Autopsy report · NCT04074590

Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis

“Sponsor decision due to strategic considerations”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 2 years 9 months before it stopped.
• 23 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Colitis, Ulcerative

Interventions

LYS006; Placebo

Participants

23

Sites

9

Countries

Bulgaria, Czechia, Germany, Poland, Russia, Slovakia

Trials that died the same way

• 99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis
  “Sponsor Decision based on strategic considerations” (98% match in meaning)
• Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
  “Strategic decision of Sponsor” (96% match in meaning)
• Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
  “Strategic sponsor decision” (95% match in meaning)
• High-Risk Skin Cancers With Atezolizumab Plus NT-I7
  “Strategic decision by sponsor” (95% match in meaning)
• Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
  “Sponsor's strategic decision” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.